{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T17:00:04Z","timestamp":1784221204952,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,29]]},"DOI":"10.7759\/cureus.83176","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T11:57:06Z","timestamp":1745927826000},"source":"Crossref","is-referenced-by-count":1,"title":["Biochemical and Plasma Lipid Responses to Pemafibrate in Patients With Primary Biliary Cholangitis and Dyslipidemia: A Four-Year Analysis"],"prefix":"10.7759","author":[{"given":"Hiroyuki","family":"Kobayashi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumi","family":"Sugiura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mizuki","family":"Koyama-Otagiri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takayuki","family":"Nimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukifumi","family":"Kurasawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haruaki","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoru","family":"Joshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(24)01303-5","article-title":"Primary biliary cholangitis","volume":"404","author":"Tanaka A","year":"2024","unstructured":"Tanaka A, Ma X, Takahashi A, Vierling JM. Primary biliary cholangitis. Lancet. 2024, 404:1053-66. 10.1016\/s0140-6736(24)01303-5","journal-title":"Lancet"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-017-0799-z","article-title":"Genetics and epigenetics in the pathogenesis of primary biliary cholangitis","volume":"11","author":"Joshita S","year":"2018","unstructured":"Joshita S, Umemura T, Tanaka E, Ota M. Genetics and epigenetics in the pathogenesis of primary biliary cholangitis. Clin J Gastroenterol. 2018, 11:11-8. 10.1007\/s12328-017-0799-z","journal-title":"Clin J Gastroenterol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajhg.2012.08.010","article-title":"Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population","volume":"91","author":"Nakamura M","year":"2012","unstructured":"Nakamura M, Nishida N, Kawashima M, et al.. Genome-wide association study identifies TNFSF15 and POU2AF1 as susceptibility loci for primary biliary cirrhosis in the Japanese population. Am J Hum Genet. 2012, 91:721-8. 10.1016\/j.ajhg.2012.08.010","journal-title":"Am J Hum Genet"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.03.017","article-title":"Association analysis of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with primary biliary cirrhosis in Japanese patients","volume":"53","author":"Joshita S","year":"2010","unstructured":"Joshita S, Umemura T, Yoshizawa K, et al.. Association analysis of cytotoxic T-lymphocyte antigen 4 gene polymorphisms with primary biliary cirrhosis in Japanese patients. J Hepatol. 2010, 53:537-41. 10.1016\/j.jhep.2010.03.017","journal-title":"J Hepatol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra043898","article-title":"Primary biliary cirrhosis","volume":"353","author":"Kaplan MM","year":"2005","unstructured":"Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med. 2005, 353:1261-73. 10.1056\/NEJMra043898","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2009.11.027","article-title":"Primary biliary cirrhosis: a 2010 update","volume":"52","author":"Poupon R","year":"2010","unstructured":"Poupon R. Primary biliary cirrhosis: a 2010 update. J Hepatol. 2010, 52:745-58. 10.1016\/j.jhep.2009.11.027","journal-title":"J Hepatol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12809","article-title":"Positive antimitochondrial antibody but normal serum alkaline phosphatase levels: could it be primary biliary cholangitis?","volume":"47","author":"Berdichevski T","year":"2017","unstructured":"Berdichevski T, Cohen-Ezra O, Pappo O, Ben-Ari Z. Positive antimitochondrial antibody but normal serum alkaline phosphatase levels: could it be primary biliary cholangitis?. Hepatol Res. 2017, 47:742-6. 10.1111\/hepr.12809","journal-title":"Hepatol Res"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.11441\/shinshumedj.66.39","article-title":"Two cases of primary biliary cholangitis with hepatocellular carcinoma in a non-cirrhotic stage","volume":"66","author":"Sugiura A","year":"2018","unstructured":"Sugiura A, Joshita S, Yamashita Y, et al.. Two cases of primary biliary cholangitis with hepatocellular carcinoma in a non-cirrhotic stage. Shinshu Med J. 2018, 66:39-49. 10.11441\/shinshumedj.66.39","journal-title":"Shinshu Med J"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12270","article-title":"Guidelines for the management of primary biliary cirrhosis: the Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan","volume":"44 Suppl S1","author":"Working Subgroup (English version) for Clinical Practice Guidelines for Primary Biliary Cirrhosis","year":"2014","unstructured":"Working Subgroup (English version) for Clinical Practice Guidelines for Primary Biliary Cirrhosis. Guidelines for the management of primary biliary cirrhosis: the Intractable Hepatobiliary Disease Study Group supported by the Ministry of Health, Labour and Welfare of Japan. Hepatol Res. 2014, 44 Suppl S1:71-90. 10.1111\/hepr.12270","journal-title":"Hepatol Res"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"European Association for the Study of the Liver","year":"2017","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017, 67:145-72. 10.1016\/j.jhep.2017.03.022","journal-title":"J Hepatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30145","article-title":"Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases","volume":"69","author":"Lindor KD","year":"2019","unstructured":"Lindor KD, Bowlus CL, Boyer J, Levy C, Mayo M. Primary biliary cholangitis: 2018 practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2019, 69:394-419. 10.1002\/hep.30145","journal-title":"Hepatology"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199105303242204","article-title":"A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group","volume":"324","author":"Poupon RE","year":"1991","unstructured":"Poupon RE, Balkau B, Eschw\u00e8ge E, Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group. N Engl J Med. 1991, 324:1548-54. 10.1056\/NEJM199105303242204","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-26531-0","article-title":"Serum autotaxin is a useful disease progression marker in patients with primary biliary cholangitis","volume":"8","author":"Joshita S","year":"2018","unstructured":"Joshita S, Umemura T, Usami Y, et al.. Serum autotaxin is a useful disease progression marker in patients with primary biliary cholangitis. Sci Rep. 2018, 8:8159. 10.1038\/s41598-018-26531-0","journal-title":"Sci Rep"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1714519","article-title":"A placebo-controlled trial of bezafibrate in primary biliary cholangitis","volume":"378","author":"Corpechot C","year":"2018","unstructured":"Corpechot C, Chazouill\u00e8res O, Rousseau A, et al.. A placebo-controlled trial of bezafibrate in primary biliary cholangitis. N Engl J Med. 2018, 378:2171-81. 10.1056\/NEJMoa1714519","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1002\/hep.30552","article-title":"Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis","volume":"70","author":"Honda A","year":"2019","unstructured":"Honda A, Tanaka A, Kaneko T, et al.. Bezafibrate improves GLOBE and UK-PBC scores and long-term outcomes in patients with primary biliary cholangitis. Hepatology. 2019, 70:2035-46. 10.1002\/hep.30552","journal-title":"Hepatology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.04.010","article-title":"Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis","volume":"75","author":"Tanaka A","year":"2021","unstructured":"Tanaka A, Hirohara J, Nakano T, et al.. Association of bezafibrate with transplant-free survival in patients with primary biliary cholangitis. J Hepatol. 2021, 75:565-71. 10.1016\/j.jhep.2021.04.010","journal-title":"J Hepatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacl.2017.10.006","article-title":"Efficacy and safety of pemafibrate (K-877), a\u00a0selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial","volume":"12","author":"Ishibashi S","year":"2018","unstructured":"Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, Yamashita S. Efficacy and safety of pemafibrate (K-877), a\u00a0selective peroxisome proliferator-activated receptor \u03b1 modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-controlled, phase 3 trial. J Clin Lipidol. 2018, 12:173-84. 10.1016\/j.jacl.2017.10.006","journal-title":"J Clin Lipidol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2016.02.029","article-title":"Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial","volume":"249","author":"Ishibashi S","year":"2016","unstructured":"Ishibashi S, Yamashita S, Arai H, et al.. Effects of K-877, a novel selective PPAR\u03b1 modulator (SPPARM\u03b1), in dyslipidaemic patients: a randomized, double blind, active- and placebo-controlled, phase 2 trial. Atherosclerosis. 2016, 249:36-43. 10.1016\/j.atherosclerosis.2016.02.029","journal-title":"Atherosclerosis"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13361","article-title":"Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis","volume":"49","author":"Joshita S","year":"2019","unstructured":"Joshita S, Umemura T, Yamashita Y, et al.. Biochemical and plasma lipid responses to pemafibrate in patients with primary biliary cholangitis. Hepatol Res. 2019, 49:1236-43. 10.1111\/hepr.13361","journal-title":"Hepatol Res"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.4166\/kjg.2021.092","article-title":"Effects of switching from fenofibrate to pemafibrate for asymptomatic primary biliary cholangitis","volume":"78","author":"Dohmen K","year":"2021","unstructured":"Dohmen K, Onohara SY, Harada S. Effects of switching from fenofibrate to pemafibrate for asymptomatic primary biliary cholangitis. Korean J Gastroenterol. 2021, 78:227-34. 10.4166\/kjg.2021.092","journal-title":"Korean J Gastroenterol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.13747","article-title":"Effects of pemafibrate on primary biliary cholangitis with dyslipidemia","volume":"52","author":"Yamaguchi M","year":"2022","unstructured":"Yamaguchi M, Asano T, Arisaka T, Mashima H, Irisawa A, Tamano M. Effects of pemafibrate on primary biliary cholangitis with dyslipidemia. Hepatol Res. 2022, 52:522-31. 10.1111\/hepr.13747","journal-title":"Hepatol Res"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.14172","article-title":"Pemafibrate improves liver biochemistry and GLOBE scores in patients with primary biliary cholangitis: nationwide, multicenter study by the Japanese Red Cross Liver Study Group","author":"Tsuji K","year":"2025","unstructured":"Tsuji K, Tamaki N, Kurosaki M, et al.. Pemafibrate improves liver biochemistry and GLOBE scores in patients with primary biliary cholangitis: nationwide, multicenter study by the Japanese Red Cross Liver Study Group. Hepatol Res. 2025, 1-10. 10.1111\/hepr.14172","journal-title":"Hepatol Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling RK","year":"2006","unstructured":"Sterling RK, Lissen E, Clumeck N, et al.. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection. Hepatology. 2006, 43:1317-25. 10.1002\/hep.21178","journal-title":"Hepatology"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50346","article-title":"A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C","volume":"38","author":"Wai CT","year":"2003","unstructured":"Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, Lok AS. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003, 38:518-26. 10.1053\/jhep.2003.50346","journal-title":"Hepatology"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2005.12.029","article-title":"Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid","volume":"130","author":"Par\u00e9s A","year":"2006","unstructured":"Par\u00e9s A, Caballer\u00eda L, Rod\u00e9s J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology. 2006, 130:715-20. 10.1053\/j.gastro.2005.12.029","journal-title":"Gastroenterology"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1002\/hep.22428","article-title":"Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis","volume":"48","author":"Corpechot C","year":"2008","unstructured":"Corpechot C, Abenavoli L, Rabahi N, et al.. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008, 48:871-7. 10.1002\/hep.22428","journal-title":"Hepatology"},{"key":"ref27","unstructured":"A trial to investigate the pharmacokinetics and safety of K-808 (pemafibrate) in primary biliary cholangitis (PBC) subjects with and without cirrhosis. (2024). Accessed. March 17, 2025: https:\/\/jrct.niph.go.jp\/en-latest-detail\/jRCT2071240023."},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.14929","article-title":"Clinical utility of FibroScan as a non-invasive diagnostic test for primary biliary cholangitis","volume":"35","author":"Joshita S","year":"2020","unstructured":"Joshita S, Yamashita Y, Sugiura A, et al.. Clinical utility of FibroScan as a non-invasive diagnostic test for primary biliary cholangitis. J Gastroenterol Hepatol. 2020, 35:1208-14. 10.1111\/jgh.14929","journal-title":"J Gastroenterol Hepatol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.7863\/ultra.33.2.197","article-title":"Shear wave elastography for evaluation of liver fibrosis","volume":"33","author":"Ferraioli G","year":"2014","unstructured":"Ferraioli G, Parekh P, Levitov AB, Filice C. Shear wave elastography for evaluation of liver fibrosis. J Ultrasound Med. 2014, 33:197-203. 10.7863\/ultra.33.2.197","journal-title":"J Ultrasound Med"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2015.118","article-title":"Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis","volume":"110","author":"Umemura T","year":"2015","unstructured":"Umemura T, Joshita S, Sekiguchi T, et al.. Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis. Am J Gastroenterol. 2015, 110:857-64. 10.1038\/ajg.2015.118","journal-title":"Am J Gastroenterol"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509840","article-title":"A placebo-controlled trial of obeticholic acid in primary biliary cholangitis","volume":"375","author":"Nevens F","year":"2016","unstructured":"Nevens F, Andreone P, Mazzella G, et al.. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016, 375:631-43. 10.1056\/NEJMoa1509840","journal-title":"N Engl J Med"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29569","article-title":"A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis","volume":"67","author":"Kowdley KV","year":"2018","unstructured":"Kowdley KV, Luketic V, Chapman R, et al.. A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis. Hepatology. 2018, 67:1890-902. 10.1002\/hep.29569","journal-title":"Hepatology"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.03220.x","article-title":"Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid","volume":"95","author":"Kurihara T","year":"2000","unstructured":"Kurihara T, Niimi A, Maeda A, Shigemoto M, Yamashita K. Bezafibrate in the treatment of primary biliary cirrhosis: comparison with ursodeoxycholic acid. Am J Gastroenterol. 2000, 95:2990-2. 10.1111\/j.1572-0241.2000.03220.x","journal-title":"Am J Gastroenterol"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04512.x","article-title":"Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid","volume":"33","author":"Levy C","year":"2011","unstructured":"Levy C, Peter JA, Nelson DR, et al.. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther. 2011, 33:235-42. 10.1111\/j.1365-2036.2010.04512.x","journal-title":"Aliment Pharmacol Ther"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13465","article-title":"Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes","volume":"43","author":"Cheung AC","year":"2016","unstructured":"Cheung AC, Lapointe-Shaw L, Kowgier M, Meza-Cardona J, Hirschfield GM, Janssen HL, Feld JJ. Combined ursodeoxycholic acid (UDCA) and fenofibrate in primary biliary cholangitis patients with incomplete UDCA response may improve outcomes. Aliment Pharmacol Ther. 2016, 43:283-93. 10.1111\/apt.13465","journal-title":"Aliment Pharmacol Ther"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2017.287","article-title":"Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response","volume":"113","author":"Reig A","year":"2018","unstructured":"Reig A, Ses\u00e9 P, Par\u00e9s A. Effects of bezafibrate on outcome and pruritus in primary biliary cholangitis with suboptimal ursodeoxycholic acid response. Am J Gastroenterol. 2018, 113:49-55. 10.1038\/ajg.2017.287","journal-title":"Am J Gastroenterol"},{"key":"ref37","article-title":"Deterioration in renal function associated with fibrate therapy","volume":"55","author":"Lipscombe J","year":"2001","unstructured":"Lipscombe J, Lewis GF, Cattran D, Bargman JM. Deterioration in renal function associated with fibrate therapy. Clin Nephrol. 2001, 55:39-44.","journal-title":"Clin Nephrol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.5551\/jat.44412","article-title":"Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, placebo-controlled, double-blind, randomized trial","volume":"25","author":"Arai H","year":"2018","unstructured":"Arai H, Yamashita S, Yokote K, Araki E, Suganami H, Ishibashi S. Efficacy and safety of pemafibrate versus fenofibrate in patients with high triglyceride and low HDL cholesterol levels: a multicenter, placebo-controlled, double-blind, randomized trial. J Atheroscler Thromb. 2018, 25:521-38. 10.5551\/jat.44412","journal-title":"J Atheroscler Thromb"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/363010-biochemical-and-plasma-lipid-responses-to-pemafibrate-in-patients-with-primary-biliary-cholangitis-and-dyslipidemia-a-four-year-analysis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T11:57:08Z","timestamp":1745927828000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/363010-biochemical-and-plasma-lipid-responses-to-pemafibrate-in-patients-with-primary-biliary-cholangitis-and-dyslipidemia-a-four-year-analysis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,29]]},"references-count":38,"URL":"https:\/\/doi.org\/10.7759\/cureus.83176","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,29]]}}}